LIEPHARM
Last board
2 directors, 1 in day-to-day management, 1 auditor, last change in 2024Director, permanent representative
appointed by deed of 30-01-2024
term without a fixed end
also on the board of 12 other companies
Permanent representatives 1
Mandates through the years
6 names, the dashed line is todayDirector
Director
Daily management delegate
Statutory auditor
Director (not named in the articles)
Director (not named in the articles)
LeadershipBoardEarlierRest of the termmandate already running before its first mention
Mandates as a list
-
- Director, appointed by deed of 30-01-2024, still in office
-
- Director, appointed by deed of 30-01-2024, still in office
-
- Daily management delegate, appointed by deed of 30-01-2024, still in office
-
- Statutory auditor, appointed by deed of 30-01-2024, still in office
-
- Director (not named in the articles), from 20-01-2015 to 30-01-2024
- Manager, until 17-01-2024
-
- Director (not named in the articles), appointed by deed of 17-01-2024, until 30-01-2024
- Manager, until 17-01-2024
Control
Shareholder
This company
LIEPHARM
Equity €281,357
Profit €45,375 in 2023
Capital
- Contribution
- €23,100
- Source
- deed of 17-01-2024
Owners through the years
as the annual accounts name themOwners as a list
-
- 2021 to 2023: 100%
Source: lists of holdings in the owners' accounts
Articles of association
deed of 17-01-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
Capital transactions
Shareholders according to the deeds
Stated in the deed
deed of 23-07-2024 ↗
- 100%
Stated in the deed
deed of 27-05-2024 ↗
- all shares
Capital over time
- 17-01-2024 Converted to unavailable equity · €23,100